Niewczas MA, et al. Circulating TNF Receptors 1 and 2 Predict ESRD in Type 2 Diabetes. J Am Soc Nephrol. 2012 Mar;23(3):507-15. doi: 10.1681/ASN.2011060627 Gohda T, et al. Circulating TNF Receptors 1 and 2 Predict Stage 3 CKD in Type 1 Diabetes. J Am Soc Nephrol. 2012 Mar;23(3):516-24. doi: 10.1681/ASN.2011060628 La néphropathie […]
Meier JJ et al. Pancreatic diabetes manifests when beta cell area declines by approximately 65% in humans. Diabetologia. 2012 Jan 28. [Epub ahead of print]. doi: 10.1007/s00125-012-2466-8 Le diabète, quelle qu’en soit l’étiologie, est en principe associé à une diminution de la masse de cellules β pancréatiques [1]. Le pancréas étant un organe […]
Dennedy MC, Avalos G, O’Reilly MW, O’Sullivan EP, Gaffney G, Dunne F. ATLANTIC-DIP: raised maternal body mass index (BMI) adversely affects maternal and fœtal outcomes in glucose-tolerant women according to International Association of Diabetes and Pregnancy Study Groups (IADPSG) criteria. J Clin Endocrinol Metab 2012 Feb 8 [Epub ahead of print]. doi: 10.1210/jc.2011-2674 […]
Gunawardana S.C. et al. Reversal of type 1 diabetes in mice by brown adipose tissue transplant. Diabetes. 2012 ; 61 : 674-682. doi: 10.2337/db11-0510 Les temps changent, les paradigmes aussi… L’insuline a été longtemps (et le demeure toujours en pratique) le seul traitement du diabète de type 1 (DT1), qui se caractérise par […]
Gupta RK, et al. Zfp423 expression identifies committed preadipocytes and localizes to adipose endothelial and perivascular cells. Cell Metab. 2012 Feb 8;15(2):230-9. doi: 10.1016/j.cmet.2012.01.010 Tran V-K, et al. The Vascular Endothelium of the Adipose Tissue Gives Rise to Both White and Brown Fat Cells. Cell Metab. 2012 Feb 8;15(2):222-9. doi: 10.1016/j.cmet.2012.01.008 Le […]
Meta-analysis of individual patient data in randomised trials of self monitoring of blood glucose in people with non-insulin treated type 2 diabetes. Farmer AJ, Perera R, Ward A, Heneghan C, Oke J, Barnett AH, Davidson MB, Guerci B, Coates V, Schwedes U, O’Malley S. BMJ. 2012 Feb 27;344:e486. doi: 10.1136/bmj.e486 L’autosurveillance glycémique (ASG) […]
Burant CF, Viswanathan P, Marcinak J, Cao C, Vakilynejad M, Xie B, Leifke E. TAK-875 versus placebo or glimepiride in type 2 diabetes mellitus: a phase 2, randomised, double-blind, placebo-controlled trial. Lancet, published online February 27, 2012. doi: 10.1016/S0140-6736(11)61879-5 GPR40 (G Protein-coupled Receptor 40) ou FFAR1 (Free Fatty Acid Receptor 1) appartient à […]
Stein E.A. et al. Effect of a monoclonal antibody to PCSK9 on LDL cholesterol. N Engl J Med. 2012 ; 366: 1108-18. doi: 10.1056/NEJMoa1105803 PCSK9 (Proprotein Convertase Subtilisin/Kexin type 9) est une proprotéine convertase qui agit comme un inhibiteur naturel du récepteur au LDL-cholestérol (LDL-C) [pour revue 1, 2]. PCSK9 est principalement exprimée […]
Sakai M, et al., CITED2 links hormonal signaling to PGC-1α acetylation in the regulation of gluconeogenesis. Nat Med. 2012 Mar 18;18(4):612-7. doi: 10.1038/nm.2691 Wang Y, et al., Inositol-1,4,5-trisphosphate receptor regulates hepatic gluconeogenesis in fasting and diabetes. Nature. 2012 Apr 8;485(7396):128-32. doi: 10.1038/nature10988 S’il fallait réduire la physiopathologie de l’hyperglycémie du diabète de […]
TODAY Study Group. A Clinical Trial to Maintain Glycemic Control in Youth with Type 2 Diabetes. N Engl J Med. 2012 Apr 29. [Epub ahead of print]. doi: 10.1056/NEJMoa1109333 Un diabète découvert à l’adolescence est traditionnellement diagnostiqué comme étant un diabète de type 1, par argument de fréquence. Cela correspond toujours à une […]
Lorem ipsum dolor sit amet, consectetur adipiscing elit
Manage Consent
To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Functional
Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes.The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
